Routine CMO appointment with no change in business outlook. The inducement stock grant at-the-money signals management's confidence in pipeline progression but creates modest future dilution (~150k shares). Monitor upcoming Phase 3 data readouts for fasedienol (social anxiety disorder) as the primary catalyst for VTGN.
VTGN drugs
VTGN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 20 $0.6400entry
- T+1 · 6mo ago 0.00%α −0.19% · $0.6400
- T+5 · 6mo ago −1.56%α −3.36% · $0.6300
- T+20 · 5mo ago +4.72%α +3.98% · $0.6702
- T+60 · 3mo ago −58.19%α −63.19% · $0.2676
Price Chart
How similar events traded
Executive Summary
Vistagen appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026, with a base salary of $425,000, a $50,000 signing bonus, and an inducement stock option for 150,000 shares at $0.5955/share. This is a routine C-level appointment that fills a key clinical leadership role for a late-stage biopharmaceutical company focused on Phase 3 fasedienol for social anxiety disorder.
Key Facts
- Appointed Angel S. Angelov, MD, MBA as Chief Medical Officer effective May 18, 2026
- Annual base salary of $425,000; eligible for annual discretionary cash bonus with initial target of 45% of base salary
- Received $50,000 signing bonus (50% upon start, 50% at six-month anniversary)
- Granted inducement stock option to purchase 150,000 shares at $0.5955 per share (closing price on May 18, 2026)
- Option vests 25% on one-year anniversary, remainder monthly over 36 months; 10-year term
- Company entered into standard indemnification agreement with Dr. Angelov
- Dr. Angelov previously served as CMO at Theranica and held VP-level roles at Karuna Therapeutics, Neurocrine Biosciences
Financial Impact
Compensation costs of $425k salary plus $50k signing bonus; option grant of 150k shares represents approximately 1.4% dilution based on $24M market cap and $0.5955 option price (implied shares outstanding ~40M)
Risk Factors
- No new clinical data or pipeline catalysts in this filing
- Inducement grants add to shareholder dilution over next 4 years
- Company is pre-revenue clinical-stage with $24M market cap, limited margin for error on Phase 3 trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-036492 |
| Document: vtgn-20260518.htm | 0001628280-26-036492 |
| Document: vtgn8-kex99120260519.htm | 0001628280-26-036492 |
| Document: 0001628280-26-036492-index-headers.html | 0001628280-26-036492 |
| Document: 0001628280-26-036492-index.html | 0001628280-26-036492 |
| Document: 0001628280-26-036492.txt | 0001628280-26-036492 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers